Basil A Horst
Overview
Explore the profile of Basil A Horst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huber R, Lee J, Borretta L, Tessier-Cloutier B, Lum A, Yip S, et al.
Hum Pathol
. 2024 Jan;
144:34-39.
PMID: 38224873
The majority of melanocytic proliferations can be readily categorized as benign or malignant based on histologic assessment under the microscope by a trained dermatopathologist. However, a subset of lesions, termed...
2.
Shaigany S, Tessier-Cloutier B, Busam K, Horst B
Hum Pathol
. 2020 Sep;
106:32-38.
PMID: 32946880
Primary dermal melanoma (PDM) is a rare variant of melanoma which simulates metastatic melanoma to the skin. Diagnosis of PDM cannot be established on histologic grounds alone but requires absence...
3.
Yip R, Lee L, Lee L, Schaeffer D, Horst B, Yang H
Virchows Arch
. 2020 Jun;
477(1):167.
PMID: 32474731
No abstract available.
4.
Zhu M, Burugu S, Gao D, Yu J, Kos Z, Leung S, et al.
Mod Pathol
. 2020 May;
33(9):1753-1763.
PMID: 32350416
Glucocorticoid-induced TNF receptor (GITR) is an emerging immunotherapy target that is expressed at high levels on regulatory T cells. Agonistic anti-GITR antibodies have anti-tumor activity in cancer mouse models, and...
5.
Gartrell-Corrado R, Chen A, Rizk E, Marks D, Bogardus M, Hart T, et al.
Cancer Res
. 2020 Jan;
80(5):1078-1087.
PMID: 31948941
Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding of the tumor immune microenvironment (TIME) is required to stratify patients...
6.
Yip R, Lee L, Lee L, Schaeffer D, Horst B, Yang H
Virchows Arch
. 2020 Jan;
476(4):551-559.
PMID: 31897816
Lymphocytic gastritis (LG) is an uncommon reaction pattern of gastric injury characterized by intraepithelial lymphocytosis of the surface foveolar epithelium and chronic inflammation in the lamina propria. It most commonly...
7.
Kulkarni P, Robinson E, Pradhan J, Gartrell-Corrado R, Rohr B, Trager M, et al.
Clin Cancer Res
. 2019 Oct;
26(5):1126-1134.
PMID: 31636101
Purpose: Biomarkers for disease-specific survival (DSS) in early-stage melanoma are needed to select patients for adjuvant immunotherapy and accelerate clinical trial design. We present a pathology-based computational method using a...
8.
Gartrell R, Marks D, Rizk E, Bogardus M, Gerard C, Barker L, et al.
Clin Cancer Res
. 2019 Jan;
25(8):2494-2502.
PMID: 30647081
Purpose: Biomarkers are needed to stratify patients with stage II-III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity....
9.
Yip R, Lee L, Schaeffer D, Horst B, Yang H
Melanoma Res
. 2018 Sep;
28(6):645-647.
PMID: 30256271
Immune checkpoint inhibitors such as programmed cell death-1 inhibitor pembrolizumab have been shown to be effective in metastatic malignancies such as advanced melanoma. Immune-related adverse effects on multiple organs have...
10.
Blake Z, Marks D, Gartrell R, Hart T, Horton P, Cheng S, et al.
J Immunother Cancer
. 2018 Apr;
6(1):25.
PMID: 29622046
Background: Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management...